| BACKGROUND
Lung cancer is one of the most harmful diseases which associates with cancer deaths around the world, with more than 220 000 new diagnoses and nearly 158 000 deaths occurring in the United States in 2016. 1 Non-small cell lung cancer occupied nearly 85% of lung cancer cases; it was composed primarily of squamous cell carcinoma (SCC) and adenocarcinoma. 2 In spite of advances in the diagnosis and current molecular targeted therapies, the overall 5-year survival rate is only 18%. 1 Consequently, there is an urgent assignment to investigate the potential molecular mechanisms of lung tumorigenesis and identify novel therapeutic targets, which can enhance the survival probability for patients with lung cancer.
MicroRNAs (miRNAs) are defined as small non-coding RNAs with a length of about 20-25 nucleotides, which exert pivotal effects in various biological processes. 3 miRNAs can regulate gene expression at post-transcriptional level through 3′-untranslated region (3′UTR) pairing with target gene mRNAs. 4 miRNAs regulate various targets which have critical roles in a wide spectrum of biological processes, including tumorigenesis and development, cell proliferation, metastasis, invasion and apoptosis. 5 In addition, miRNA participated in almost all of the essential signalling pathways, including the expression of many important tumour-associated genes such as oncogenes and tumour suppressors. 6 The identification of alteration in miRNA levels is associated with various human cancers including NSCLC. 7 A large number of studies have shown that the identification of various risk factors and biomarkers could help to better comprehend the cellular and molecular alterations involved in the cancer progress including NSCLC. In addition, it would be a better monitor of NSCLC patients for therapy by using a powerful diagnostic and prognostic biomarker. 8 miRNAs have appeared to be novel diagnostic, therapeutic and prognostic biomarkers in NSCLC patients among various recommended biomarkers such as DNAs, RNAs, proteins, epigenetic changes and glycoproteins.
9
Several lines of evidence have confirmed that miRNAs were related to molecular pathological changes and signalling cascades of lung cancer. 10 Additionally, dysregulation of these molecules could be associated with inhibition and/or activation of several cellular and molecular therapy targets, which have functions in tumorigenesis and development of NSCLC. 11 miRNAs were considered to be novel candidates for the diagnosis and therapy of NSCLC, as it could be detected with non-invasive and comparatively easy assay methods.
Moreover, the discovery of miRNA in exosomes opened an attractive world that they could play an important role in diagnosing patients with NSCLC as significant biomarkers. 12 Exosomes were drivers as small vesicles (50-150 nm) of endocytic initially, which released from many different cell types, such as tumour cells, stem cells, mesenchymal cells, thrombocytes and some normal cells. 13 There is emerging evidence that suggest that vesicles could carry various cargos such as DNA, mRNAs, miRNAs and proteins. It has been reported that secretion of exosomes could result in alteration in the behaviour of cancer cells or tumours. 14, 15 As a proof concept, exosomes might be applied as significant diagnostic and therapeutic biomarkers in NSCLC patients.
In this paper, we summarize a variety of tissue-specific miRNAs and circulating miRNAs with high sensitivity and specificity which could be used as potential diagnostic and therapeutic biomarkers in NSCLC patients. In addition, we emphasize that the miRNA-derived exosomes become novel diagnostic biomarkers potentially in these patients with NSCLC.
| FEATURES OF MIRNA
The miRNAs are endogenous small (19-22 nucleotides), non-coding RNAs which play pivotal roles in various biological processes. 3 The miRNA genes are typically transcribed from RNA polymerase II into long primary transcripts, which are up to several kilobases (primiRNA). 16 Then they undergo a further step that processes it into shorter hairpin sequences of approximately 70 nucleotides (premiRNA) by the nuclear microprocessor complex formed by the RNase III Drosha 17 and DiGeorge syndrome critical region gene 8 (DGCR8). 18 Next, these pre-miRNA are transported into the cytoplasm carried out by RNase III Dicer to form a double-stranded RNA. 19 Generally, one of the chains is chosen to act as the mature miRNA through the Argonaut proteins to enter the RNA-induced silencing complex (RISC), while the remaining complementary chain is degraded. The miRNA recognizes target genes based on sequence complementarity, primarily to the 3′-UTR of the target mRNAs. Moreover, miRNA modulates the translation of proteins through binding to their target mRNA.
4,20-
22 So miRNA mediates translational repression or degradation of mRNAs depending on the degree of homology to their 3′-UTR target sequence, and miRNA could regulate gene expression emerged in multiple signalling participating in carcinoma growth, dissemination, metastatic and even rejection to therapy. 23 Accordingly, dysregulated miRNA will contribute to a variety of pathological events, including cancer initiation and progression.
| MECHANISMS OF MIRNA IN CANCER
It is essential to maintain normal cellular homeostasis through controlling of miRNA levels precisely. During the past years, it is a critical task to determine the mechanisms of how the miRNA was dysregulated in cancer.
Several miRNA genes are located in cancer-related genomic regions or in fragile sites; miRNA is highly susceptible to genomic alterations of solid tumours and haematological malignancies. 24 Calin 
| MIRNA FUNCTION IN CANCER
The development of cancer is a multi-step process that involves multiple alterations in oncogenes and tumour suppressor genes over a period of time, generally over several years. Cancer-associated miRNA have been known as 'onco-miRs', which play critical roles as oncogenes and/or tumour suppressors. A variety of studies suggested that miRNA would play a critical role as tumour suppressors or oncogenes.
Valuably, they modulate almost all cell functions including apoptosis, proliferation, cell cycle, differentiation, stem cell maintenance and metabolism. 23 Selected functional miRNAs and their targets in NSCLC are summarized in Figure 1 .
| Tumour suppressor
It is reported that the miR-34 family was down-regulated in cancer tissues compared with normal tissues, and decreased expression of miR-34a was associated with a worse prognosis of cancer. 34 Bommer et al 35 The miRNA encoded by the let-7 family (including 12 human homologues) are considered to be tumour inhibitors because they map to brittle sites associated with lung, breast, urothelial and cervical cancers. 26 It has been shown that the inhibition of oncogenes, such as rat sarcoma (RAS), myelocytomatosis oncogene (Myc), the high mobility group AThook 2 (HMGA2), cyclin D2, cyclin-dependent kinase 6 (CDK6) and cell division cycle 25A (CDC25A) in cellular growth and proliferation, led to suppression of cancer cell proliferation and cell cycle distribution. 37 Takamizawa et al 38 observed that the expression of let-7 frequently decreased in lung cancer both in vitro and in vivo; in addition, the down-regulated let-7 was significantly associated with poor post-operative survival, independently with the state of disease. 
| CLINICAL APPLICATIONS OF MIRNA IN NSCLC
Early diagnosis of NSCLC is important for prognosis and can lead to reducing mortality rate in patients. 52 After describing these examples of how miRNA target specific pathways that are important for NSCLC, an important and compelling application is to concern miRNA to be used as biomarkers in the clinic. The discovery of sensitive and specific biomarkers for NSCLC will improve current treatment of malignant disease and early detection of cancer.
Another important task is how to detect the miRNA in panels of different haematological and solid cancer types. Quantitative real-time reverse transcription PCR (qRT-PCR) is a quantitative gold standard for gene expression and it is one of the most common methods for detecting low levels of miRNA with high sensitivity and specificity. 53, 54 Recently, enzymatic luminescence miRNA assay, for example, quantitative bioluminescence assay, has been proposed as suitable for clinical diagnostic. This assay is designed for rapid and sensitive miRNA expression analysis based on isothermal rolling circle amplification.
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Over the years, hybridization based-methods have improved such as in situ hybridization (ISH) with locked nucleic acid probes. 56 Microarray method 57 is widely used to screen large numbers of miRNAs simultaneously. Moreover, the appearance of deep-sequencing methods consider to be a new star which depend on next-generation sequencing machines that can process millions of sequence reads in parallel in just a few days, has driven to detect most of the miRNA. 58 Circulating miRNA, which presented in serum, plasma, urine, saliva and other human body fluids, is often detected by high-throughput profiling techniques, sequencing and miRNA microarray combined with qRT-PCR.
59-61
Shen et al 62 identified that miR-145 was down-regulated in poorly differentiated NSCLC specimens; moreover, the relative expression levels of miR-145 in stage II and III were significantly lower than those in stage I. In terms of miR-126, it was associated with tumour stage and lymph nodes metastasis, suggesting that miR-126 might play a key role in the progression and metastasis of NSCLC. 63 Stenvold et al 64 also found that miR-182 has tumour suppressor properties in stage II and in SCC patients, suggesting miR-182 tended to be a favourable prognostic factor in the total NSCLC cohorts. In addition, the expression of miR-451 in NSCLC tissues was also associated with poor degree of tumour differentiation, advanced pathological stage, lymph node metastasis and poor prognosis. 65 These clinical data suggested that miRNA could act as pivotal part for the detection of novel diagnostic, prognostic and therapeutic biomarkers in patients with NSCLC.
| Tissue-specific miRNA as diagnostic, prognostic and therapeutic biomarkers in NSCLC
miRNAs appeared to become a novel valuable diagnostic candidates, and would be more advanced than other various biomarkers, which are employed for the diagnosis of NSCLC in early stages. 66 It has been shown that significantly different miRNA expression profiles emerged in human tumours, 7 and the dysregulated expression patterns of miRNA were detected with high sensitivity and specificity. 67 Moreover, miRNA has an advantage with high stability. 68 These evidences speculated that miRNA may have potential to play a crucial role in cancer.
Recently, there were a large number of studies identifying upregulation or down-regulation of a variety of tissue-specific miRNAs in NSCLC. 69 Surgical resection remains the most effective treatment of early-stage NSCLC. 36 Up to this point, many patients with NSCLC still develop tumour metastasis and recurrence after receiving pulmonary resection procedure, due to lack of promising biomarkers for the diagnosis, prognosis, and therapy of lung cancer. 70 Gao These results suggested that miR-9600 could play an important role as potential therapeutic biomarkers in NSCLC patients.
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Integrin subunit beta 1 (ITGB1) is an essential subgroup of the integrin family, which plays an important role in regulating cellextracellular matrix (ECM) adhesion and signalling, affecting various of cellular processes, including cell proliferation, apoptosis, metastasis, invasion and survival. 101 It has been observed that positive expression or activation of ITGB1 signalling was associated with poor prognosis in lung cancer. 102 Epithelial-mesenchymal transition is a pivotal process that promotes tumour cells to obtain a more migratory and invasive mesenchymal phenotype, during which tumour cells exert downregulation of the expression of epithelial proteins such as E-cadherin, while up-regulation of the expression of mesenchymal proteins such as N-cadherin and vimentin (VIM; Figure 2 ). 103 Qin et al 104 demonstrated that miR-134 down-regulated ITGB1 expression and inhibited EMT, resulting in suppressed migration and invasion of NSCLC both in vitro and in vivo. These researches indicated that miR-134 might be applied as a novel therapeutic biomarkers in patients with NSCLC.
104 Table 1 illustrates a large number of miRNAs and their targets that are involved in lung cancer pathogenesis and could be used as diagnostic, prognostic and therapeutic biomarkers in this disease.
| CIRCULATING MIRNAS AS DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN NSCLC
A large number of studies have suggested circulating miRNA was known as a miRNA released into bloodstream. 105 Chen et al and
Mitchell et al 106, 107 revealed that large amounts of circulating miRNA were detected stably in serum and plasma, which could be used as Circulating miRNA could be a novel attractive option for the diagnosis and treatment of several diseases including lung cancer. Multiple lines of evidence has revealed that dysregulation of circulating miRNA could be used as potential diagnostic and therapeutic biomarkers in NSCLC. [108] [109] [110] [111] [112] [113] [114] [115] [116] Circulating miR-422a may provide a potential target for therapeutic approaches in management of lung cancer. 117 Wu et al 117 These findings suggested that these circulating miRNA could exert effects as attractive option to diagnose patients with NSCLC. 118 Dinh et al 119 showed from an unbiased screen that miR-29a and miR-150 were decreased in the circulation of NSCLC patients undergoing thoracic RT: thoracic radiotherapy. Table 2 illustrates a number of circulating miRNA which might be applied as diagnostic and therapeutic biomarkers for lung cancer patients. naive MSCs into a novel kind of pro-inflammatory MSCs (P-MSCs) by activating TLR2/NF-kB signalling through exosomal surface HSP70.
| EXOSOMAL MIRNA AS DIAGNOSTIC BIOMARKERS IN NSCLC
Finally, these results confirmed that exosomal RNAs and miRNAs, and proteins might exert effects as potential diagnosis biomarkers in lung cancer patient. 132 Table 3 indicates a number of exosomal miRNA released from lung cancer cell.
| CONCLUSION AND PERSPECTIVE
Non-small cell lung cancer is the most common serious cancer and a leading cause of cancer-related death worldwide. 
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